UCB announces BRIVIACT (brivaracetam) now approved by FDA to treat partial-onset (focal) seizures in pediatric epilepsy patients Read more
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies Read more
Novartis announces FDA approval of Gilenya as the first disease-modifying therapy for pediatric relapsing multiple sclerosis Read more